

# Natalia Mitiushkina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2480574/publications.pdf>

Version: 2024-02-01

38  
papers

853  
citations

516710

16  
h-index

477307

29  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1359  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive evaluation of the test for 5â€™-3â€™ end <sc>mRNA</sc> unbalanced expression as a screening tool for <sc>ALK</sc> and <sc>ROS1</sc> fusions in lung cancer. <i>Cancer Medicine</i> , 2022, , .	2.8	8
2	Preparation of Duplex Sequencing Libraries for Archival Paraffin-Embedded Tissue Samples Using Single-Strand-Specific Nuclease P1. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4586.	4.1	1
3	Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study. <i>Translational Oncology</i> , 2021, 14, 101121.	3.7	6
4	The effect of SLC6A3 variable number of tandem repeats and methylation levels on individual susceptibility to start tobacco smoking and on the ability of smokers to quit smoking. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 117-123.	1.5	6
5	Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28220.	1.5	24
6	Comparative analysis of expression of mutant and wild-type alleles is essential for reliable PCR-based detection of MET exon 14 skipping. <i>Biochimie</i> , 2019, 165, 267-274.	2.6	10
7	First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. <i>Clinical Drug Investigation</i> , 2018, 38, 553-562.	2.2	8
8	Spectrum of APC and MUTYH germline mutations in Russian patients with colorectal malignancies. <i>Clinical Genetics</i> , 2018, 93, 1015-1021.	2.0	16
9	Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants. <i>Biochimie</i> , 2018, 154, 19-24.	2.6	14
10	EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts. <i>Oncology Research and Treatment</i> , 2018, 41, 634-642.	1.2	8
11	The genotypes and methylation of MAO genes as factors behind smoking behavior. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 394-401.	1.5	14
12	Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression. <i>Oncology Research and Treatment</i> , 2016, 39, 605-614.	1.2	6
13	BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study. <i>Melanoma Research</i> , 2016, 26, 442-447.	1.2	5
14	Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 401-406.	3.8	30
15	Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 502-505.	1.3	16
16	Distinct benefit from crizotinib in lung cancer patients carrying distinct ALK translocations: is fluorescent hybridization in situ testing still sufficient to guide clinical decisions?. <i>Translational Cancer Research</i> , 2016, 5, S1393-S1395.	1.0	0
17	Effect of genotype and methylation of CYP2D6 on smoking behaviour. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 531-540.	1.5	17
18	Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients. <i>Cancer Letters</i> , 2015, 359, 259-261.	7.2	32

#	ARTICLE	IF	CITATIONS
19	Novel ALK fusion partners in lung cancer. <i>Cancer Letters</i> , 2015, 362, 116-121.	7.2	75
20	Biased detection of guanine-rich microRNAs by array profiling: Systematic error or biological phenomenon?. <i>Journal of Computational Science</i> , 2014, 5, 351-356.	2.9	5
21	Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 553-562.	2.5	51
22	High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients. <i>International Journal of Cancer</i> , 2014, 134, 2352-2358.	5.1	31
23	Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2014, 9, e31-e33.	1.1	12
24	Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. <i>Medical Oncology</i> , 2013, 30, 686.	2.5	43
25	Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation. <i>Familial Cancer</i> , 2013, 12, 129-132.	1.9	13
26	Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. <i>Cancer Cytopathology</i> , 2013, 121, 370-376.	2.4	48
27	High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. <i>International Journal of Cancer</i> , 2012, 130, 2867-2873.	5.1	58
28	High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 1049-1059.	2.5	25
29	Evidence for depletion of CASP5 Ala90Thr heterozygous genotype in aged subjects. <i>Experimental Gerontology</i> , 2010, 45, 726-729.	2.8	4
30	High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. <i>Onkologie</i> , 2010, 33, 231-238.	0.8	39
31	Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. <i>Cancer Letters</i> , 2009, 278, 183-191.	7.2	37
32	Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing. <i>Hereditary Cancer in Clinical Practice</i> , 2009, 7, 2.	1.5	3
33	Role of CYP2D6 gene polymorphism in individual's ability to quit smoking. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 206.	2.2	0
34	Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. <i>Familial Cancer</i> , 2007, 6, 281-286.	1.9	67
35	High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. <i>European Journal of Cancer</i> , 2006, 42, 1380-1384.	2.8	70
36	BRCA1 4153delA founder mutation in Russian ovarian cancer patients. <i>Hereditary Cancer in Clinical Practice</i> , 2006, 4, 193.	1.5	12

#	ARTICLE	IF	CITATIONS
37	CHEK2 1100delC mutation is frequent among Russian breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 99-102.	2.5	32
38	Apoptosis-deficient Pro allele of gene is associated with the resistance of psoriasis to the UV-based therapy. <i>Journal of Dermatological Science</i> , 2005, 37, 185-187.	1.9	7